Upstate Active Clinical Trials
Study Title:
Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and NeckWhat is the purpose of the study? (in Layman's terms, please describe the study)
We are doing the second part of this study because we want to find out if radiation therapy with docetaxel and cetuximab or radiation therapy with cisplatin and an immunotherapy drug, atezolizumab, is better than the usual approach for your high-risk head and neck cancer. The usual approach is defined as care most people get for high-risk head and neck cancer.Upstate Institutional Review Board (IRB) Number:
501348Study/Protocol ID:
RTOG-1216Study Phase:
II/IIIPatient Age Group:
AdultsPrincipal Investigator:
Seung Shin Hahn, MDWhat is involved if I participate?
- How long is the study?
10 years - Is transportation provided or reimbursed?
No - Is parking provided or reimbursed?
Yes - What tests and procedures are involved?
Usual approach of radiation therapy with cisplatin chemotherapy OR
Radiation therapy with docetaxel and cetuximab chemotherapy OR
Radiation therapy with cisplatin chemotherapy and the study drug, atezolizumab
Where will the study take place?
Downtown Cancer CenterCommunity Cancer Center
Verona Medical Oncology and Radiation Oncology
Oswego Medical Oncology and Radiation Oncology
The Hill Medical Center Radiation Oncology
Other Information:
https://clinicaltrials.gov/study/NCT01810913ClinicalTrials.Gov ID:
NCT01810913For more information about this trial go to ClinicalTrials.Gov
Who can I contact for more information?
Name: Laine Abernathy
Phone: 315-464-6528
Email: [email protected]